Carcinogenesis, Vol. 24, No. 3, 453-459,
March 2003
© 2003 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models
1 Department of Anatomy and Biology, Osaka Medical College, 2–7, Daigaku-machi, Takatsuki, Osaka 569-8686, Japan,
2 Laboratory of Cell Regulation and Carcinogenesis, Division of Basic Science, Building 41, Room C619, 41 Library Dr. and
3 Medicine Branch, National Cancer Insititute, National Institutes of Health, Bethesda, MD 20892, USA
The effects of lovastatin, a potent inhibitor of HMG CoA reductase, on experimental mammary and prostate oncogenesis, were studied in vitro and in vivo. Lovastatin inhibited cell growth in vitro in a dose-dependent manner for both mammary and prostate cancer cell lines, which was associated with p53-independent apoptosis. Flow cytometric analyses of lovastatin-treated mammary and prostate cancer cells demonstrated cell-cycle G1 arrest, as well as decreases in S and G2/M fractions. p21Waf1 and p27Kip1 were induced by lovastatin in both types of cancer cells. Gene expression profiling of cells treated with lovastatin, however, was remarkable for a paucity of transcriptional changes induced by lovastatin. Treatment with lovastatin for 4 weeks did inhibit the formation of pre-neoplastic mammary intraepithelial neoplasias (MIN) in vivo, but not invasive carcinomas in the C3(1)/SV40 TAg transgenic model of mammary cancer. The decreased multiplicity of MIN lesions was associated with increased levels of apoptosis in these lesions. However, cell proliferation in the mammary lesions was not significantly different between lovastatin-treated and control mice 1 day after lovastatin treatment. In female mice treated with lovastatin for 12 weeks, there was a tendency for reduced tumor volume, which did not reach statistical significance. However, lovastatin did not suppress any lesion formation in the prostate of C3(1)/SV40 TAg transgenic male mice. Our results suggest that as lovastatin exerts an inhibitory effect on the development of early mammary lesions of mammary carcinogenesis, this compound may be useful for the chemoprevention of mammary cancer and might have utility as an adjuvant in breast cancer therapy. The chemopreventive effects of lovastatin in vivo, however, may be tissue-specific.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. B. Wali, S. V. Bachawal, and P. W. Sylvester Combined Treatment of {gamma}-Tocotrienol with Statins Induce Mammary Tumor Cell Cycle Arrest in G1 Exp Biol Med, June 1, 2009; 234(6): 639 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Lubet, D. Boring, V. E. Steele, J. M. Ruppert, M. M. Juliana, and C. J. Grubbs Lack of Efficacy of the Statins Atorvastatin and Lovastatin in Rodent Mammary Carcinogenesis Cancer Prevention Research, February 1, 2009; 2(2): 161 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lu, H. Xiao, H. You, Y. Lin, H. Jin, B. Snagaski, and C. S. Yang Synergistic Inhibition of Lung Tumorigenesis by a Combination of Green Tea Polyphenols and Atorvastatin Clin. Cancer Res., August 1, 2008; 14(15): 4981 - 4988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Murtola, T. L.J. Tammela, J. Lahtela, and A. Auvinen Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2226 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Jacobs, C. Rodriguez, E. B. Bain, Y. Wang, M. J. Thun, and E. E. Calle Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2213 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. McAnally, J. Gupta, S. Sodhani, L. Bravo, and H. Mo Tocotrienols Potentiate Lovastatin-Mediated Growth Suppression In Vitro and In Vivo Exp Biol Med, April 1, 2007; 232(4): 523 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sprague and M. Wood Breast cancer prevention: time for randomized controlled trials with statins. Arch Intern Med, May 22, 2006; 166(10): 1143 - 1144. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shannon, S. Tewoderos, M. Garzotto, T. M. Beer, R. Derenick, A. Palma, and P. E. Farris Statins and Prostate Cancer Risk: A Case-Control Study Am. J. Epidemiol., August 15, 2005; 162(4): 318 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Khanna, M. Plummer, V. Nilakantan, and G. M. Pieper Recombinant p21 Protein Inhibits Lymphocyte Proliferation and Transcription Factors J. Immunol., June 15, 2005; 174(12): 7610 - 7617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Horiguchi, M. Sumitomo, J. Asakuma, T. Asano, T. Asano, and M. Hayakawa 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis Clin. Cancer Res., December 15, 2004; 10(24): 8648 - 8655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Shibata, Y. Ito, J. Morimoto, and Y. Otsuki Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism Carcinogenesis, October 1, 2004; 25(10): 1887 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Robbins Statins Sentence Thyroid Cancer Cells to Death Rho J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3019 - 3020. [Full Text] [PDF]
|
|